��ࡱ�>�� 
E

������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~�Root Entry��������0S*���
F
@
Workbook������������z�SummaryInformation(

�����DocumentSummaryInformation8��������������������������������������������������������������������������������������������������������������������������������������������

































!
"
#
$
%
&
'
(
)
*
+
,
-
.
/
0
1
2
3
4
5
6
7
8
9
:
;
<
=
>
?
@
A
B
C
D
������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������ F�������\psshxbrlB�a
�
=
8
  ��
�
=�ZL,�8
X@�"
�
�1���

Tahoma1���

Tahoma1���

Tahoma1���

Tahoma1���
Tahoma1���


Tahoma1���
!
Tahoma7
"$"#,##0_);\( "$"#,##0\ )A
"$"#,##0_);[Red]\( "$"#,##0\ )C
"$"#,##0.00_);\( "$"#,##0.00\ )M$
"$"#,##0.00_);[Red]\( "$"#,##0.00\ )q*6
_("$"* #,##0_);_("$"* \( #,##0\ );_("$"* "-"_);_( @_ )_)-
_(* #,##0_);_(* \( #,##0\ );_(* "-"_);_( @_ )�,>
_("$"* #,##0.00_);_("$"* \( #,##0.00\ );_("$"* "-"??_);_( @_ )o+5
_(* #,##0.00_);_(* \( #,##0.00\ );_(* "-"??_);_( @_ )#�
$#,##0;($#,##0)�
#,##0;(#,##0)/�
$#,##0.##;($#,##0.##)��� � �
�� �A �
�� �A ��� �A ��� �A ��� �A ��� �A ��� �A ��� �A ��� �A ��� �A ��� �A ��� �A ��� �A ��� �A �
� �
+�� �A �
)�� �A �
,�� �A �
*�� �A �
�� �A �
� �
(� �
*� �
(� � � � (� � � ��
� ��
� �
� ��
� ��
� ��
� ��
� �
� ������������������`
�0�
Document Information�,/
Entity Information�F�
Consolidated Statements of Inco�>�'
Consolidated Balance Sheets�F�2
Consolidated Balance Sheets Par�F�6
Consolidated Statements of Shar�F�K
Consolidated Statements of Cash�F�X
Significant Accounting Policies�0~Z
Acquisition of Wyeth�Fq\
Other Significant Transactions �Fd^
Cost-Reduction Initiatives and �<W`
Collaborative Arrangements�Jb
Other�&=d
Taxes on Income�<0f
Other Comprehensive Income�2#h
Financial Instruments�j
Inventories�B l
Property, Plant and Equipment�F�m
Goodwill and Other Intangible A�F�o
Pension and Postretirement Bene��q
Equity�0�s
Share-Based Payments�:�u
Earnings Per Common Share�*�w
Lease Commitments��y
Insurance�F�{
Legal Proceedings and Contingen�F�}
Segment, Geographic and Revenue�F�
Quarterly Consolidated Financia�

�
�
T�
� 


Document Information.
12 Months Ended Dec. 31, 2009 USD / shares 
Document information
Document type
10-K
Amendment flag
false
Document period end date
2009-12-31
Entity Information (USD $)
In Billions, except Share data
12 Months Ended Dec. 31, 2009 
Feb. 18, 2010 
Jun. 26, 2009 
Entity Information [Line Items]
Entity registrant name
PFIZER INC
Entity central index key
0000078003
Current fiscal year end date
--12-31!
Entity well known seasoned issuer
Yes
Entity voluntary filers
No
Entity current reporting status
Entity filer category
Large Accelerated Filer
Entity public float
Entity Listings [Line Items]&
Entity common stock shares outstanding)
Consolidated Statements of Income (USD $)"
In Millions, except Per Share data
12 Months Ended Dec. 31, 2008
12 Months Ended Dec. 31, 2007 
Revenues
Costs and expenses:
Cost of sales [1]
[1]6
Selling, informational and administrative expenses [1]%
Research and development expenses [1]!
Amortization of intangible assets?
Acquisition-related in-process research and development charges;
Restructuring charges and certain acquisition-related costs
Other (income)/deductions-netF
Income from continuing operations before provision for taxes on income
Provision for taxes on income!
Income from continuing operations"
Discontinued operations-net of tax8
Net income before allocation to noncontrolling interests9
Less: Net income attributable to noncontrolling interests&
Net income attributable to Pfizer Inc.
Earnings per common share-basicQ
Income from continuing operations attributable to Pfizer Inc. common shareholders:
Net income attributable to Pfizer Inc. common shareholders!
Earnings per common share-diluted
Weighted-average shares-basic
Weighted-average shares-diluted�
[1]Exclusive of amortization of intangible assets except as disclosed in Note 1L. Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.#
Consolidated Balance Sheets (USD $)
In Millions
Dec. 31, 2009 
Dec. 31, 2008 
Assets
Cash and cash equivalents
Short-term investmentsO
Accounts receivable, less allowance for doubtful accounts: 2009-$176; 2008-$190
Short-term loans
Inventories4
Current deferred tax assets and other current assets
Assets held for sale
Total current assets
Long-term investments and loans<
Property, plant and equipment, less accumulated depreciation
Goodwill=
Identifiable intangible assets, less accumulated amortization:
Noncurrent deferred tax assets and other noncurrent assets
Total assets$
Liabilities and Shareholders' EquityW
Short-term borrowings, including current portion of long-term debt: 2009-$27; 2008-$937
Accounts payable
Dividends payable
Income taxes payable&
Accrued compensation and related items>
Current deferred tax liabilities and other current liabilities
Total current liabilities
Long-term debt
Pension benefit obligations"
Postretirement benefit obligations#
Noncurrent deferred tax liabilities
Other taxes payable
Other noncurrent liabilities
Total liabilitiesi
Preferred stock, without par value, at stated value; 27 shares authorized; issued: 2009-1,511; 2008-1,804W
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2009-8,869; 2008-8,863
Additional paid-in capital
Employee benefit trusts4
Treasury stock, shares at cost; 2009-799; 2008-2,117
Retained earnings0
Accumulated other comprehensive income/(expense)&
Total Pfizer Inc. shareholders' equity/
Equity attributable to noncontrolling interests
Total shareholders' equity*
Total liabilities and shareholders' equity2
Consolidated Balance Sheets Parentheticals (USD $)
In Millions, except Share data
Allowance for doubtful accounts!
Current portion of long-term debt-
Preferred stock, without par, at stated value"
Preferred stock, shares authorized
Preferred stock, shares issued.
Common stock, par value (in dollars per share)
Common stock, share authorized
Common stock, shares issued
Treasury stock, shares at cost7
Consolidated Statements of Shareholders' Equity (USD $)
PREFERRED STOCK 
COMMON STOCK 
ADD'L PAID-IN CAPITAL 
EMPLOYEE BENEFIT TRUSTS < 
TREASURY STOCK 
RETAINED EARNINGS
ACCUM. OTHER COMP. INC./(EXP.) 
SHAREHOLDERS' EQUITY 
NON-CONTROLLING INTERESTS 
Total !
Balance, (value) at Dec. 31, 2006,
Balance, Beginning (shares) at Dec. 31, 2006
Comprehensive income:
Net income2
Other comprehensive income / (expense), net of tax
Total comprehensive income.
Adoption of new accounting standard-net of tax
Cash dividends declared-
common stock
preferred stock"
Stock option transactions (shares)!
Stock option transactions (value)"
Purchases of common stock (shares)!
Purchases of common stock (value)0
Employee benefit trust transactions-net (shares)/
Employee benefit trust transactions-net (value)4
Preferred stock conversions and redemptions (shares)3
Preferred stock conversions and redemptions (value)
Other (shares)
Other (value),
Balance, Beginning (shares) at Dec. 31, 2007!
Balance, (value) at Dec. 31, 2007,
Balance, Beginning (shares) at Dec. 31, 2008!
Balance, (value) at Dec. 31, 2008
Acquisition of Wyeth (shares)
Acquisition of Wyeth (value)
noncontrolling interests;
Purchase of subsidiary shares from noncontrolling interests,
Balance, Beginning (shares) at Dec. 31, 2009!
Balance, (value) at Dec. 31, 2009-
Consolidated Statements of Cash Flows (USD $)
Operating Activitiesq
Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
Share-based compensation expenseJ
Certain intangible asset impairments and other associated non-cash charges
Gains on disposals2
(Gains)/losses on sales of discontinued operations)
Deferred taxes from continuing operations
Other non-cash adjustmentsH
Changes in assets and liabilities, net of acquisitions and divestitures:
Accounts receivable
Other assets(
Accounts payable and accrued liabilities
Taxes
Other liabilities)
Net cash provided by operating activities
Investing Activities*
Purchases of property, plant and equipmentQ
Purchases of short-term investments with original maturities greater than 90 daysk
Proceeds from redemptions and sales of short-term investments with original maturities greater than 90 daysm
Proceeds from redemptions and sales of short-term investments with original maturities of 90 days or less-net"
Purchases of long-term investments<
Proceeds from redemptions and sales of long-term investments"
Acquisitions, net of cash acquired
Other investing activities3
Net cash (used in)/provided by investing activities
Financing Activities%
Increase in short-term borrowings-net/
Principal payments on short-term borrowings-net)
Proceeds from issuances of long-term debt$
Principal payments on long-term debt
Purchases of common stock
Cash dividends paid
Other financing activities3
Net cash provided by/(used in) financing activities<
Effect of exchange-rate changes on cash and cash equivalents5
Net (decrease)/ increase in cash and cash equivalents.
Cash and cash equivalents at beginning of year(
Cash and cash equivalents at end of year#
Supplemental Cash Flow Information:A
Non-cash transactions-Acquisition of Wyeth, treasury stock issued
Cash paid during the period for:
Income taxes
Interest
Significant Accounting Policies*
Significant Accounting Policies [Abstract],
Significant Accounting Policies [Text Block]�
1. Significant Accounting Policies A. Consolidation and Basis of Presentation The consolidated financial statements include our parent company and all subsidiaries, including those operating outside the United States (U.S.) and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests and we do not have significant interests in non-consolidated entities. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November30 for each year presented. Substantially all unremitted earnings of inter<
national subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. We made certain reclassifications to prior-period amounts to conform to the December31, 2009 presentations related to the presentation of noncontrolling interests as a result of adopting a new accounting standard. Subsequent events have been evaluated through the time of our filing on February26, 2010. On October15, 2009, we completed our acquisition of Wyeth in a cash-and-stock transaction valued at approximately $68 billion. Commencing from the acquisition date, our financial statements reflect the assets, liabilities and operating results of Wyeth. In accordance with our domestic and international fiscal year-ends, approximately two-and-a-half months of the fourth calendar quarter of 2009 in the case of Wyeths U.S. operations and approximately one-and-a-half months of the fourth calendar quarter of 2009 in the case of Wyeths international operations are included in our consolidated financial statements for the year ended December31, 2009. For additional information, see Note 2. Acquisition of Wyeth. B. New Accounting Standards As of January1, 2009, we adopted a new accounting standard that retains the purchase method of accounting for acquisitions but requires a number of changes to that method, including changes in the way assets and liabilities are recognized in purchase accounting. Specifically, they require the capitalization of in-process research and development costs at fair value and require the expensing of transaction costs as incurred. The adoption of these provisions did not have a significant impact on our consolidated financial statements upon adoption, but they did significantly impact our accounting for the acquisition of Wyeth in 2009. For additional information, see Note 2. Acquisition of Wyeth. As of January1, 2009, we adopted a new accounting standard that provides guidance for the accounting, reporting and disclosure of noncontrolling interests, previously referred to as minority interests. A noncontrolling interest represents the portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to a parent. The adoption of these provisions resulted in a number of changes to the presentation of our con
Acquisition of Wyeth
Acquisition of Wyeth [Abstract]!
Acquisition of Wyeth [Text Block]�
2. Acquisition of Wyeth A. Description of the Transaction On October15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at approximately $68 billion, in which each share of Wyeth common stock outstanding, with certain limited exceptions, was canceled and converted into the right to receive $33.00 in cash without interest and 0.985 of a share of Pfizer common stock. The stock component was valued at $17.40 per share of Wyeth common stock based on the closing market price of Pfizers common stock on the acquisition date, resulting in a total merger consideration value of $50.40 per share of Wyeth common stock. While Wyeth now is a wholly owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations. Wyeths core business was the discovery, development, manufacture and sale of prescription pharmaceutical products, including vaccines, for humans. Other operations of Wyeth included the discovery, development, manufacture and sale of consumer healthcare products (over-the-counter products), nutritionals and animal health products. Our acquisition of Wyeth has made us a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition, across developed and emerging markets. The acquisition of Wyeth also added to our pipeline of biopharmaceutical development projects endeavoring to develop medicines to help patie<
nts in critical areas, including oncology, pain, inflammation, Alzheimers disease, psychoses and diabetes. In connection with the regulatory approval process, we are required to divest certain animal health assets. Certain of these assets were sold in 2009, while others, classified as Assets held for sale, are pending disposition. B. Fair Value of Consideration Transferred The table below details the consideration transferred to acquire Wyeth: (IN MILLIONS, EXCEPT PER SHARE AMOUNTS) CONVERSION CALCULATION FAIR VALUE FORM OF CONSIDERATION Wyeth common stock outstanding as of the acquisition date 1,339.6 Multiplied by Pfizers stock price as of the acquisition date multiplied by the exchange ratio of 0.985 ($17.66(a) x 0.985) $ 17.40 $ 23,303 Pfizercommon stock(a),(b) Wyeth common stock outstanding as of the acquisition date 1,339.6 Multiplied by cash consideration per common share outstanding $ 33.00 44,208 Cash Wyeth stock options canceled for a cash payment(c) 405 Cash Wyeth restricted stock/restricted stock units and other equity-based awards canceled for a cash payment 320 Cash Total fair value of consideration transferred $ 68,236 (a) The fair value of Pfizers common stock used in the conversion calculation represents the closing market price of Pfizers common stock on the acquisition date. (b) Approximately 1.3 billion shares of Pfizer common stock, prev)
Other Significant Transactions and Events4
Other Significant Transactions and Events [Abstract]6
Other Significant Transactions and Events [Text Block]�
3. Other Significant Transactions and Events A. Formation of ViiV, an Equity-Method Investment In the fourth quarter of 2009, we completed a previously announced transaction, where we and GlaxoSmithKline plc (GSK) created a new company, ViiV Healthcare Limited (ViiV), which is focused solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We recognized a gain of approximately $482 million in connection with the formation, which is recorded in Other (income)/deductionsnet. Under the agreement, we and GSK have contributed certain existing HIV- related products, pipeline assets and research assets to ViiV and will perform RD and manufacturing services. We initially hold a 15% equity interest and GSK holds an 85% equity interest in ViiV. The equity interests will be adjusted in the event that specified sales and regulatory milestones are achieved. Our equity interest in ViiV could vary from 9% to 30.5%, and GSKs equity interest could vary from 69.5% to 91%, depending upon the milestones achieved with respect to the original assets contributed by us and by GSK to ViiV. Each company also may be entitled to preferential dividend payments to the extent that specific sales thresholds are met in respect of the marketed products and pipeline assets originally contributed. We are accounting for our interest in ViiV as an equity method investment due to the significant influence we have over the operations of ViiV through our board representation and minority veto rights. Our investment in ViiV is reported as a private equity investment in Long-term investments and loans. B. Prior-Period Acquisitions During the years ended December31, 2008 and 2007, we completed the following acquisitions in support of our commitment to capitalizing on new growth opportunities: In the fourth quarter of 2008, we completed the acquisition of a number of animal health product lines from Schering-Plough Corporation (Schering-Plough) for approximately $170 million. In the second quarter of 2008, we acquired Encysive Pharmaceuticals Inc. (Encysive), a biopharmaceutical company, through a tender offer, for approximately $200million, including transaction costs. In addition, in the second quarter of 2008, we acquired Serenex, Inc. (Serenex), a privately held biotechnology company. In connection with these acquisitions, we recorded approximately $170 m<
illion in Acquisition-related in-process research and development charges and approximately $450 million in intangible assets. In the first quarter of 2008, we acquired CovX, a privately held biotherapeutics company, and we acquired all the outstanding shares of Coley Pharmaceutical Group, Inc. (Coley), a biopharmaceutical company. In connection with these and two smaller acquisitions related to Animal Health, we recorded approximately $440 million in Acquisition-related in-process research and development charges in 2008. In 2009, we resolved certain contingencies associated with CovX and recorded $68 million in Acquisition-related in-process research and development charges. In the first quarter of 2007, we acquired BioRexis Pharmaceut8
Cost-Reduction Initiatives and Acquisition-Related CostsG
Cost - Reduction Initiatives and Acquisition - Related Costs [Abstract]E
Cost-Reduction Initiatives and Acquisition-Related Costs [Text Block]�
4. Cost-Reduction Initiatives and Acquisition-Related Costs We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October15, 2009. Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January26, 2009 have been incorporated into a comprehensive plan to integrate Wyeths operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company. We incurred the following costs in connection with our cost-reduction initiatives and the Wyeth acquisition: YEARENDEDDECEMBER31, (MILLIONS OF DOLLARS) 2009 2008 2007 Transaction costs(a) $ 768 $ $ Integration costs and other(b) 569 49 11 Restructuring charges(c) 3,000 2,626 2,523 Restructuring charges and certain acquisition-related costs 4,337 2,675 2,534 Additional depreciationasset restructuring(d) 241 786 788 Implementation costs(e) 250 819 601 Total $ 4,828 $ 4,280 $ 3,923 (a) Transaction costs represent external costs directly related to effecting the acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred are fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009. All bridge term loan commitment fees have been expensed, and we no longer are subject to the covenants under that agreement (see Note 9D: Financial Instruments: Long-Term Debt). (b) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and systems integration. (c) Restructuring charges include the following: ACTIVITY ACCRUAL COSTS INCURRED THROUGH DECEMBER31, AS OF DECEMBER31, (MILLIONS OF DOLLARS) 2009 2008 2007 2005-2009 2009(1) 2009(2) Employee termination costs $ 2,571 $ 2,004 $ 2,034 $ 7,721 $ 4,488 $ 3,233 Asset impairments 159 543 260 1,452 1,452 Other 270 79 229 710 577 133 Total $ 3,000 $ 2,626 $ 2,523 $ 9,883 $ 6,517 $ 3,366 (1) Includes adjustments for foreign currency translation. (2) Included in Current deferred tax liabilities and other current liabilities ($2.5billion) and Other noncurrent liabilities ($846 million). From the beginning of our cost-reduction and transformation <
initiatives in 2005 through December31, 2009, Employee ter
Collaborative Arrangements%
Collaborative Arrangements [Abstract]'
Collaborative Arrangements [Text Block]�
5. Collaborative Arrangements In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development, that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product. The amounts and classifications in our consolidated statements of income of payments (income/(expense)) between us and our collaboration partners follow: YEARENDEDDECEMBER31, (MILLIONS OF DOLLARS) 2009 2008 2007 RevenuesRevenues(a) $ 593 $ 488 $ 473 RevenuesAlliance revenues(b) 2,925 2,251 1,789 Total revenues from collaborative arrangements 3,518 2,739 2,262 Cost of sales(c) (166 ) (147 ) (166 ) Selling, informational and administrative expenses(d) 10 75 94 Research and development expenses(e) (361 ) (476 ) (444 ) (a) Represents sales to our partners of products manufactured by us. (b) Substantially all relate to amounts earned from our partners under co-promotion agreements. (c) Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners. (d) Represents net reimbursements from our partners for selling, informational and administrative expenses incurred. (e) Primarily related to net reimbursements, as well as upfront payments and milestone payments earned by our partners. The upfront and milestone payments were as follows: $150 million in 2009, $300 million in 2008 and $330 million in 2007. The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated with the products under the collaborative arrangements. In 2009, Other (income)/deductionsnet includes income of $20 million paid to us for the termination of a collaboration agreement and income of $17 million paid to us as our share of profit from a collaboration partner. In 2007, we capitalized $68 million of milestone payments associated with approved products. 
Other (Income) Deductions-Net*
Other (Income)/Deductions - Net [Abstract]*
Other (Income)/Deductions-Net [Text Block]�
6. Other (Income)/DeductionsNet The components of Other (income)/deductionsnet follow: YEAR ENDED DECEMBER 31, (MILLIONS OF DOLLARS) 2009 2008 2007 Interest income $ (746 ) $ (1,288 ) $ (1,496 ) Interest expense 1,233 516 397 Net interest (income)/expense(a) 487 (772 ) (1,099 ) Royalty-related income(b) (243 ) (673 ) (224 ) Net gain on asset disposals(c) (188 ) (14 ) (326 ) Legal matters, net(d) 234 3,300 46 Gain related to ViiV(e) (482 ) Asset impairment and other associated charges(f) 417 143 28 Other, net 67 48 (184 ) Other (income)/deductionsnet $ 292 $ 2,032 $ (1,759 ) (a) Net interest expense was $487 million in 2009 compared to net interest income of $772 million in 2008. Interest expense increased in 2009 due to our issuance of $13.5 billion of senior unsecured<
notes on March24, 2009 and approximately $10.5 billion of senior unsecured notes on June3, 2009, of which virtually all of the proceeds were used to partially finance the Wyeth acquisition (see Note 2. Acquisition of Wyeth). Interest income decreased in 2009 due to lower interest rates, partially offset by higher average cash balances. The decrease in net interest income in 2008 compared to 2007 was due primarily to lower net financial assets and lower interest rates during 2008 compared to 2007. Capitalized interest expense totaled $34 million in 2009, $46 million in 2008 and $43 million in 2007. (b) In 2008, includes $425 million related to the sale of certain royalty rights. (c) In 2009, primarily represents gains on sales of certain equity investments. In 2007, included a gain of $211 million related to the sale of a building in Korea. Net gains also include realized gains and losses on sales of available-for-sale securities: In 2009, 2008 and 2007, gross realized gains were $186 million, $20 million and $8 million, respectively. In 2009, gross realized losses were $43 million and none in both 2008 and 2007. Proceeds from the sale of available-for-sale securities were $27.0billion in 2009, $2.2billion in 2008 and $663 million in 2007. (d) In 2008, primarily includes charges of $2.3 billion related to the resolution of certain investigations concerning Bextra and various other products, and charges of $900 million related to our agreements and our agreements-in-principle to resolve certain litigation and claims involving our non-steroidal anti-inflammatory (NSAID) pain medicines (see Note 3C. Other Significant Transactions and Events: Bextra and Certain Other Investigations, and Note 3D. Other Significant Transactions and Events: Certain Product LitigationCelebrex and Bextra). (e) Represents a gain related to ViiV, a new equity method investment, which is focused solely on research, development and commercialization of HIV medicines (see Note 3A. Other Significant Transactions and Events: Formation of ViiV, an Equity-Method Investment). (f) 2009 amounts primarily represent asse
Taxes on Income
Taxes on Income [Abstract]
Taxes on Income [Text Block]�
7. Taxes on Income A. Taxes on Income Income from continuing operations before provision for taxes on income, and income attributable to noncontrolling interests consist of the following: YEAR ENDEDDECEMBER31, (MILLIONS OF DOLLARS) 2009 2008 2007 United States $ (3,632 ) $ (1,760 ) $ 242 International 14,459 11,454 9,036 Total income from continuing operations before provision for taxes on income $ 10,827 $ 9,694 $ 9,278 The decrease in domestic income from continuing operations before taxes in 2009 compared to 2008 was due primarily to an increase in certain expenses incurred in connection with the Wyeth acquisition, which was partially offset by the non-recurrence of charges of $2.3 billion recorded in 2008 resulting from an agreement-in-principle with the DOJ to resolve the previously reported investigations regarding past off-label promotional practices concerning Bextra and certain other investigations, as well as other litigation-related charges recorded in 2008 of approximately $900 million associated with the resolution of certain litigation involving our NSAID pain medicines. The decrease in domestic income from continuing operations before taxes in 2008 compared to 2007 was due primarily to the aforementioned charges and an increase in restructuring charges in 2008 compared to 2007, partially offset by the charges associated with Exubera in 2007. The increase in international income from continuing operations before taxes in 2009 compared to 2008 was due primarily to the gain in connection with the formation of ViiV, the decrease in international restructuring charges and the non-recurrence of acquired IPRD, partially offset by an increase in amortization expenses incurred in connection with the Wyeth acquisition. The increase <
in international income from continuing operations before taxes in 2008 compared to 2007 was due primarily to the charges associated with Exubera in 2007. For additional information on all of these charges, see Note 3. Other Significant Transactions and Events. Provision for taxes on income consists of the following: YEARENDEDDECEMBER31, (MILLIONS OF DOLLARS) 2009 2008 2007 United States: Taxes currently payable: Federal $ 10,169 $ 707 $ 1,393 State and local 71 154 243 Deferred income taxes: Federal (10,002 ) 106 (1,774 ) State and local (93 ) (136 ) (212 ) Total U.S. tax (benefit)/provision(a), (b) $ 145 $ 831 $ (350 ) International: Taxes currently payable $ 1,539 $ 2,115 $ 2,175 Deferred income taxes 513 (1,301 ) (802 ) Total international tax provision $ 2,052 $ 814 $ 1,373 Total provision for taxes on income(c) $ 2,197 $ 1,645 $ 1,023 (a) The increase in Federal current tax payable in 2009 was due to increased tax costs associated with certain business decisions executed t$
Other Comprehensive Income (Expense)/
Other Comprehensive Income/(Expense) [Abstract]1
Other Comprehensive Income/(Expense) [Text Block]�
8. Other Comprehensive Income/(Expense) Changes, net of tax, in accumulated other comprehensive income/(expense) and the components of comprehensive income follow: NET UNREALIZED GAINS /(LOSSES) BENEFIT PLANS ACCUMULATED OTHER COMPREHENSIVE INCOME/(EXPENSE) (MILLIONS OF DOLLARS) CURRENCY TRANSLATION ADJUSTMENT AND OTHER DERIVATIVE FINANCIAL INSTRUMENTS AVAILABLE FOR-SALE SECURITIES ACTUARIAL GAINS/ (LOSSES) PRIOR SERVICE (COSTS)/ CREDITS AND OTHER Balance, January1, 2007 $ 2,227 $ (26 ) $ 96 $ (2,739 ) $ (27 ) $ (469 ) Other comprehensive income/(expense)Pfizer Inc(a): Foreign currency translation adjustments 1,422 1,422 Unrealized holding gains/(losses) 3 (43 ) (40 ) Reclassification adjustments to income(b) (96 ) 3 (8 ) (101 ) Actuarial gains and other benefit plan items 1,374 11 1,385 Amortization of actuarial losses and other benefit plan items 248 7 255 Curtailments and settlementsnet 268 (5 ) 263 Other 6 (62 ) (6 ) (62 ) Income taxes 313 (12 ) 9 (656 ) (8 ) (354 ) 2,768 Balance, December31, 2007 3,872 (32 ) 54 (1,567 ) (28 ) 2,299 Other comprehensive income/(expense)Pfizer Inc.(a): Foreign currency translation adjustments (5,898 ) (5,898 ) Unrealized holding gains/(losses) 69 (193 ) (124 ) Reclassification adjustments to income(b) (2 ) (20 ) (22 ) Actuarial gains/(losses) and other benefit plan items (3,098 ) 22 (3,076 ) Amortization of actuarial losses and other benefit plan items 130 3 133 Curtailments and settlementsnet 280 3 283 Other 10 129 35 174 Income taxes 629 (9 ) 73 994 (25 ) 1,662 (6,868 <
) Balance, December31, 2008 (1,389 ) 28 (86 ) (3,132 ) 10 (4,569 ) Other comprehensive income/(expense)Pfizer Inc.(a): Foreign currency translation adjustments 4,978 4,978 Unrealized holding gains/(losses) 291 576 867 Reclassification adjustments to income(b) 5 (299 ) (143 ) (437 ) Actuarial gains/(losses) and other benefit plan items 
Financial Instruments
Financial Instruments [Abstract]"
Financial Instruments [Text Block]�
9. Financial Instruments A. Selected Financial Assets and Liabilities Information about certain of our financial assets and liabilities follows: ASOFDECEMBER31, (MILLIONS OF DOLLARS) 2009 2008 Selected financial assets measured at fair value on a recurring basis(a): Trading securities(b) $ 184 $ 190 Available-for-sale debt securities(c) 32,338 30,061 Available-for-sale money market funds(d) 2,569 398 Available-for-sale equity securities, excluding money market funds(c) 281 319 Derivative financial instruments in receivable positions(e): Foreign currency swaps 798 128 Foreign currency forward-exchange contracts 502 399 Interest rate swaps 276 732 Total 36,948 32,227 Other selected financial assets(f): Short-term loans, carried at cost 1,195 824 Held-to-maturity debt securities, carried at amortized cost(c) 812 2,349 Private equity securities, carried at cost 811 182 Long-term loans, carried at cost 784 1,568 Total 3,602 4,923 Total selected financial assets 40,550 37,150 Financial liabilities measured at fair value on a recurring basis(a): Derivative financial instruments in a liability position(g): Foreign currency swaps 528 153 Foreign currency forward-exchange contracts 237 1,083 Interest rate swaps 25 7 Total 790 1,243 Other financial liabilities(f),(h): Short-term borrowings, carried at historical proceeds, as adjusted(i) 5,469 9,320 Long-term debt, carried at historical proceeds, as adjusted(j), (k) 43,193 7,963 Total 48,662 17,283 Total selected financial liabilities $ 49,452 $ 18,526 (a) Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. Virtually all of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are $77 million as of December31, 2009 and $87 million as of December31, 2008 of investments that use Level 1 inputs in the calculation of fair value. None of our financial assets and liabilities measured at fair value on a recurring basis is valued using Level 3 inputs at December31, 2009 or 2008. (b) Trading securities are held in trust for legacy Pharmacia severance benefits. (c) Gross unrealized gains and losses are not significant. (d) Includes approximately $1.2 billion of money market funds held in escrow to secure certain of Wyeths payment obligations under its 1999 Nationwide Class Action Settlem
Inventories [Abstract]
Inventories [Text Block]�
10. Inventories The components of inventories follow: ASOFDECEMBER31, (MILLIONS OF DOLLARS) 2009 2008 Finished goods $ 5,249 $ 2,024 Work-in-process 5,77<
6 1,527 Raw materials and supplies 1,378 830 Total inventories(a),(b) $ 12,403 $ 4,381 (a) Increase primarily due to the acquisition of Wyeth inventories, which were recorded at fair value (see Note 2. Acquisition of Wyeth for additional detail). Wyeth inventories included pre-launch inventory associated with Prevnar/Prevenar 13 Infant which did not launch until 2010. Prevnar/Prevenar 13 Infant was approved by the EU member states in December 2009 and in the U.S. in February 2010. (b) Certain amounts of inventories are in excess of one years supply, including the pre-launch inventory associated with Prevnar/Prevenar 13 Infant. These excess amounts are primarily attributable to biologics inventory acquired from Wyeth at fair value and the quantities are generally consistent with the normal operating cycle of such inventory. There are no recoverability issues associated with these quantities. 
Property, Plant and Equipment(
Property, Plant and Equipment [Abstract]*
Property, Plant and Equipment [Text Block]+
11. Property, Plant and Equipment The major categories of property, plant and equipment follow: USEFULLIVES (YEARS) AS OF DECEMBER 31, (MILLIONS OF DOLLARS) 2009 2008 Land $ 937 $ 616 Buildings 331/3-50 14,186 8,775 Machinery and equipment 8-20 12,236 9,583 Furniture, fixtures and other 3-121/2 4,599 4,350 Construction in progress 1,966 1,804 33,924 25,128 Less: Accumulated depreciation 11,144 11,841 Total property, plant and equipment(a) $ 22,780 $ 13,287 (a) Increase primarily due to the acquisition of Wyeth property, plant and equipment, which was recorded at fair value (see Note 2. Acquisition of Wyeth for additional detail). $
Goodwill and Other Intangible Assets/
Goodwill and Other Intangible Assets [Abstract]1
Goodwill and Other Intangible Assets [Text Block]�
12. Goodwill and Other Intangible Assets A. Goodwill The changes in the carrying amount of goodwill for the years ended December31, 2009 and 2008 follow: (MILLIONS OF DOLLARS) BIOPHARMACEUTICAL DIVERSIFIED OTHER TOTAL Balance as of January1, 2008 $21,256 $ 126 $ $ 21,382 Additions(a) 21 36 57 Other(b) 40 (15 ) 25 Balance, December31, 2008 21,317 147 21,464 Additions(a) 19,954 19,954 Other(b) 848 26 84 958 Balance as of December31, 2009 $22,165 $ 173 $ 20,038 $ 42,376 (a) In 2009, $20.0 billion relates to our acquisition of Wyeth and is subject to change upon completion of our allocation of the consideration transferred to the assets acquired and liabilities assumed from Wyeth (see Note 2. Acquisition of Wyeth). The allocation of goodwill among reporting units has not yet been completed but will be completed within one year from the Wyeth acquisition date, October15, 2009. In 2008, primarily related to our acquisitions of Coley and a number of animal health product lines from Schering-Plough, as well as two smaller animal health acquisitions. (b) In 2009, primarily relates to foreign exchange, partially offset by a reduction of approximately $150 million in Biopharmaceutical in connection with the formation of ViiV (see Note 3A. Other Significant Transactions and Events: Formation of ViiV, an Equity-Method Investment for additional information.) In 2008, primarily relates to tax adjustments and the impact of foreign exchange. B. Other Intangible Assets The components of identifiable intangible assets, primarily included in Biopharmaceutical follow: AS OF DECEMBER 31, 2009 2008 (MILLIONS OF DOLLARS) GROSS CARRYING AMOUNT ACCUMULATED AMORIZATION IDENTIFIABLE INTANGIBLE ASSETS, LESS ACCUMULATED AMORTIZATION GROSS CARRYING AMOUNT ACCUMULATED AMORTIZATION IDENTIF<
IABLE INTANGIBLE ASSETS, LESS ACCUMULATED AMORTIZATION Finite-lived intangible assets: Developed technology rights $ 68,870 $ (21,223 ) $ 47,647 $ 31,484 $ (17,673 ) $ 13,811 Brands 1,637 (535 ) 1,102 1,016 (487 ) 529 License agreements 622 (119 ) 503 246 (78 ) 168 Trademarks 113 (73 ) 40 118 (78 ) 40 Other(a) 488 (231 ) 257 531 (291 ) 240 Total amortized finite-lived intangible assets 71,730 (22,181 ) 49,549 33,395 (18,607 ) 14,788 Indefinite-lived intangible assets: Brands 12,562 12,562 2,860 2,860 In-process research and development 5,834 5,834 Trademarks 68 68 70 70 Other 2 2 3 3 Total indefinite-lived intangible assets 18,466 18,466 2,933 2,G
Pension and Postretirement Benefit Plans and Defined Contribution PlansR
Pension and Postretirement Benefit Plans and Defined Contribution Plans [Abstract]T
Pension and Postretirement Benefit Plans and Defined Contribution Plans [Text Block]�
13. Pension and Postretirement Benefit Plans and Defined Contribution Plans We provide defined benefit pension plans and defined contribution plans for the majority of our employees worldwide. In the U.S., we have both qualified and supplemental (non-qualified) defined benefit plans. A qualified plan meets the requirements of certain sections of the Internal Revenue Code, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees and may not discriminate in favor of highly compensated employees in its coverage, benefits or contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical and life insurance benefits to certain retirees and their eligible dependents through our postretirement plans. In 2009, we assumed all of Wyeths defined benefit obligations and related plan assets for qualified and non-qualified pension plans and postretirement plans in connection with our acquisition of Wyeth (see Note 2. Acquisition of Wyeth). A. Components of Net Periodic Benefit Costs and Other Amounts Recognized in Other Comprehensive (Income)/Expense The annual cost and other amounts recognized in other comprehensive (income)/expense of the U.S. qualified, U.S. supplemental (non-qualified) and international pension plans and postretirement plans follow: YEAR ENDED DECEMBER 31, PENSION PLANS U.S. QUALIFIED U.S. SUPPLEMENTAL (NON-QUALIFIED) INTERNATIONAL POSTRETIREMENT PLANS (MILLIONS OF DOLLARS) 2009 2008 2007 2009 2008 2007 2009 2008 2007 2009 2008 2007 Service cost $ 252 $ 236 $ 282 $ 24 $ 23 $ 27 $ 188 $ 249 $ 292 $ 39 $ 39 $ 42 Interest cost 526 459 447 53 38 55 342 388 349 145 141 137 Expected return on plan assets (527 ) (646 ) (693 ) (375 ) (437 ) (381 ) (26 ) (35 ) (36 ) Amortization of: Actuarial losses 212 32 65 31 29 45 30 43 96 18 28 42 Prior service costs/(credits) 2 3 8 (2 ) (2 ) (2 ) (3 ) 1 (3 ) 1 1 Curtailments and settlementsnet 110 32 58 (2 ) 120 <
5 4 3 (155 ) (3 ) 10 5 Special termination benefits 61 30 16 137 8 25 29 24 17 17 Less: Amounts included in discontinued operations (27 ) Net periodic benefit costs 636 146 156 241 208 130 194 
Equity
Equity [Abstract]
Equity [Text Block]�
14. Equity A. Common Stock In connection with our acquisition of Wyeth on October15, 2009, we issued approximately 1.3 billion shares of common stock, which were previously held as Pfizer treasury stock, to former Wyeth shareholders to partially fund the acquisition (see Note 2. Acquisition of Wyeth for additional details). The excess of the average cost of Pfizer treasury stock issued over the fair value of the stock portion of the consideration transferred to acquire Wyeth was recorded as a reduction to Retained Earnings. We purchase our common stock via privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase programs, which are authorized by our Board of Directors, are available for general corporate purposes. On June23, 2005, we announced that the Board of Directors authorized a $5 billion share-purchase plan (the 2005 Stock Purchase Plan). On June26, 2006, we announced that the Board of Directors increased the authorized amount of shares to be purchased under the 2005 Stock Purchase Plan from $5 billion to $18 billion. On January23, 2008, we announced that the Board of Directors had authorized a new $5 billion share-purchase plan, to be funded by operating cash flows, that may be utilized from time to time. In total, under the 2005 Stock Purchase Plan, through December31, 2009, we purchased approximately 710million shares for approximately $18.0 billion. We did not purchase any shares of our common stock in 2009. During 2008, we purchased 26million shares of our common stock at an average price per share of $18.96, and during 2007, we purchased 395million shares of our common stock at an average price per share of $25.27. B. Preferred Stock The Series A convertible perpetual preferred stock is held by an Employee Stock Ownership Plan (Preferred ESOP) Trust and provides dividends at the rate of 6.25%, which are accumulated and paid quarterly. The per share stated value is $40,300 and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holders option, into 2,574.87 shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock or, a combination of both at a price of $40,300 per share. C. Employee Stock Ownership Plans We have two employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the company (Common ESOP). As of January1, 2008, the legacy Pharmacia U.S. savings plan was merged with the Pfizer Savings Plan. Prior to the merger, a portion of the matching contributions for legacy Pharmacia U.S. savings plan participants was funded through the ESOPs. In January 2007, we paid the remaining balance of financing, which was outstanding prior to our acquisition of Pharmacia in 2003, relating to the Preferred ESOP. C
Share-Based Payments!
Share - Based Payments [Abstract]!
Share-Based Payments [Text Block]�
15. Share-Based Payments Our compensation programs can include share-based payments. In 2009, 2008 and 2007, the primary share-based awards and their general terms and conditions are as follows: Stock options, which, when vested, entitle the holder to purchase a specified number of shares of Pfizer common stoc<
k at a price per share equal to the market price of Pfizer common stock on the date of grant. Restricted stock units (RSUs), which, when vested, entitle the holder to receive a specified number of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such RSUs. Performance share awards (PSAs) and performance-contingent share awards (PCSAs), which, when vested, entitle the holder to receive a number of shares of Pfizer common stock, within a range of shares from zero to a specified maximum, calculated using a non-discretionary formula that measures Pfizers performance relative to an industry peer group. Dividend equivalents accumulate on PSAs and are paid at the end of the vesting term in respect of any shares that are paid. Short-term incentive awards, which entitle the holder to receive a specified dollar value on the first anniversary of the grant date, based upon performance. At the election of the holder, such specified dollar value is paid: (i)in the case of senior management, all in RSUs, or half in RSUs and half in cash; and (ii)in the case of all other holders, all in RSUs, all in cash, or half in RSUs and half in cash. Stock appreciation rights (SARs), also referred to as Total Shareholder Return Units (TSRUs), which entitle the holder to receive, two years after the end of the vesting term, a number of shares of Pfizer common stock with a value equal to the difference between the defined settlement price and the closing market price of Pfizer common stock on the date of grant, plus accumulated dividend equivalents through the payment date. The Companys shareholders approved the amendment and restatement of the 2004 Stock Plan at the Annual Meeting of Shareholders held on April23, 2009. The primary purpose of the amendment was to increase the number of shares of common stock available for grants by 425million shares. In addition, the amendment provided other changes including that the number of stock options, SARs or other performance-based awards that may be granted to any one individual during any 36-month period is limited to 8million shares and that RSUs, PSAs and restricted stock grants count as two shares, while stock options and SARs count as one share, toward the maximums for the incremental 425million shares. As of December31, 2009, 499million shares were available for award, which included 0.8million shares available for award through February13, 2010 under the Pharmacia Long-Term Incentive plan (the Pharmacia Plan). Such amounts do not include 41million shares previously issuable but no longer available for award under the Pharmacia Plan, as amended and restated. The 2004 Stock Plan, as amended, is the only Pfizer plan under which equity-based compensation may currently be awarded to executives and other employees. The Compan
Earnings Per Common ShareA
Earnings Per Share Attributable to Common Shareholders [Abstract]&
Earnings Per Common Share [Text Block]�
16. Earnings per Common Share Basic and diluted EPS were computed using the following common share data: YEAR ENDED DECEMBER 31, (IN MILLIONS) 2009 2008 2007 EPS NumeratorBasic: Income from continuing operations attributable to Pfizer Inc. $ 8,621 $ 8,026 $ 8,213 Less: Preferred stock dividendsnet of tax 2 3 4 Income from continuing operations attributable to Pfizer Inc. common shareholders 8,619 8,023 8,209 Discontinued operationsnet of tax 14 78 (69 ) Net income attributable to Pfizer Inc. common shareholders $ 8,633 $ 8,101 $ 8,140 EPS DenominatorBasic: Weighted-average number of common shares outstanding 7,007 6,727 6,917 EPS NumeratorDiluted: Income from continuing operations attributable to Pfizer Inc. $ 8,621 $ 8,026 $ 8,213 Less: ESOP contributionnet of tax 2 Income from continuing operations attributable to Pfizer Inc. common shareholders 8,621 8,026 8,<
211 Discontinued operationsnet of tax 14 78 (69 ) Net income attributable to Pfizer Inc. common shareholders $ 8,635 $ 8,104 $ 8,142 EPS DenominatorDiluted: Weighted-average number of common shares outstanding 7,007 6,727 6,917 Common-share equivalentsstock options, stock issuable under employee compensation plans and convertible preferred stock 38 23 22 Weighted-average number of common shares outstanding and common-share equivalents 7,045 6,750 6,939 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(a) 400 489 514 (a) These common stock equivalents were outstanding during 2009, 2008 and 2007 but were not included in the computation of diluted EPS for those years because their inclusion would have had an anti-dilutive effect. 
Lease Commitments
Lease Commitments [Abstract]
Lease Commitments [Text Block]�
17. Lease Commitments We lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay directly for taxes, insurance, maintenance and other operating expenses or to pay higher rent when operating expenses increase. Rental expense, net of sublease income, was $364 million in 2009, $370 million in 2008 and $398 million in 2007. This table shows future minimum rental commitments under non-cancelable operating leases as of December31 for the following years: (MILLIONS OF DOLLARS) 2010 2011 2012 2013 2014 AFTER 2014 Lease commitments $ 266 $ 183 $ 144 $ 119 $ 97 $ 890
Insurance
Insurance [Abstract]
Insurance [Text Block]
18. Insurance Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our results of operations in any particular period (see Note 19. Legal Proceedings and Contingencies). #
Legal Proceedings and Contingencies.
Legal Proceedings and Contingencies [Abstract]0
Legal Proceedings and Contingencies [Text Block]�
19. Legal Proceedings and Contingencies We and certain of our subsidiaries are involved in various patent, product liability, consumer, commercial, securities, environmental and tax litigations and claims; government investigations; and other legal proceedings that arise from time to time in the ordinary course of our business. We do not believe any of them will have a material adverse effect on our financial position. Beginning in 2007 upon the adoption of a new accounting standard, we record accruals for income tax contingencies to the extent that we conclude that a tax position is not sustainable under a more likely than not standard and we record our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction when we conclude that the potential recovery is more likely than not (see Note 1P. Significant Accounting Policies: Income Tax Contingencies). We record accruals for all other contingencies to the extent that we conclude their occurrence is probable and the related damages are estimable, and we record anticipated recoveries under existing insurance contracts when assured of recovery. If a range of liability is probable and estimable and some amount within the range appears to be a better estimate than any other amount within the range, we accrue that amount. If a range of liability is probabl<
e and estimable and no amount within the range appears to be a better estimate than any other amount within the range, we accrue the minimum of such probable range. Many claims involve highly complex issues relating to causation, label warnings, scientific evidence, actual damages and other matters. Often these issues are subject to substantial uncertainties and, therefore, the probability of loss and an estimation of damages are difficult to ascertain. Consequently, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for these contingencies. These assessments can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions (see Note 1C. Significant Accounting Policies: Estimates and Assumptions). Our assessments are based on estimates and assumptions that have been deemed reasonable by management. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period. Patent claims include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe we have substantial defenses to these challenges with respect to all our material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the drug at issue, which could lead to a significant loss of sales of that drug and could materially affect future results of operations. Among the principal matters pending to +
Segment, Geographic and Revenue Information
Segment Information [Abstract]
Segment Information [Text Block]�
20. Segment, Geographic and Revenue Information Business Segments Effective with the acquisition of Wyeth, we operate in the following two distinct commercial organizations, which constitute our two business segments: Biopharmaceutical consists of the Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets customer-focused units and includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and endocrine disorders, among others. Biopharmaceuticals segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Biopharmaceutical segment. Diversified includes animal health products that prevent and treat diseases in livestock and companion animals including vaccines, parasiticides and anti-infectives; consumer healthcare products that include over-the-counter healthcare products such as pain management therapies (analgesics and heat wraps), cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and personal care items; nutrition products such as infant and toddler nutritional products; and Capsugel, which represents our gelatin capsule products and services business. Diversifieds segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Diversified segment. Segment profit/(loss) is measured based on income from continuing operations before provision for taxes on income and income attributable to noncontrolling interests. Certain costs, such as significant impacts of purchase accounting for acquisitions, restructuring and acquisition-related costs, costs related to our cost-reduction initiatives and transition activity associated with our former consumer healthcare business, which was sold in 2006, are included in Corporate/Other only. This methodology is utilized by management to evaluate our businesses. Each segment is managed separately and offers differ<
ent products requiring different marketing and distribution strategies. We sell our products primarily to customers in the wholesale sector. In 2009, sales to our three largest U.S. wholesaler customers represented approximately 17%, 11% and 10% of total revenues and, collectively, represented approximately 13% of accounts receivable as of December31, 2009. In 2008, sales to our three largest U.S. wholesaler customers represented approximately 16%, 10% and 10% of total revenues and, collectively, represented approximately 19% of accounts receivable as of December31, 2008. These sales and related accounts receivable were concentrated in the Biopharmaceutical segment. Revenues exceeded $500 million in each of 13 countries outside the U.S. in 2009 and in each of 14 countries outside the U.S. in 2008. The U.S. was the only country to contribute more than 10% of total revenues in each year. Segment Revenues and Profit(a) Segment revenues and profit are as follows: 1
Quarterly Consolidated Financial Data (Unaudited)<
Quarterly Consolidated Financial Data (Unaudited) [Abstract]>
Quarterly Consolidated Financial Data (Unaudited) [Text Block]�
Quarterly Consolidated Financial Data (Unaudited) Pfizer Inc. and Subsidiary Companies QUARTER (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH(a) 2009 Revenues $ 10,867 $ 10,984 $ 11,621 $ 16,537 Costs and expenses 6,510 7,456 7,457 13,354 Acquisition-related in-process research and development charges 20 48 Restructuring charges and certain acquisition-related costs(b) 554 459 193 3,131 Income from continuing operations before provision for taxes on income 3,803 3,049 3,971 4 Provision/(benefit) for taxes on income 1,074 786 1,092 (755 ) Income from continuing operations 2,729 2,263 2,879 759 Discontinued operationsnet of tax 1 3 2 8 Net income before allocation to noncontrolling interests 2,730 2,266 2,881 767 Less: Net income attributable to noncontrolling interests 1 5 3 Net income attributable to Pfizer Inc. $ 2,729 $ 2,261 $ 2,878 $ 767 Earnings per common sharebasic(c): Income from continuing operations attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10 Discontinued operationsnet of tax Net income attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10 Earnings per common sharediluted(c): Income from continuing operations attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10 Discontinued operationsnet of tax Net income attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10 Cash dividends paid per common share $ 0.32 $ 0.16 $ 0.16 $ 0.16 Stock prices High $ 18.48 $ 15.60 $ 16.98 $ 18.99 Low $ 11.62 $ 12.75 $ 14.11 $ 16.07 (a) In accordance with our domestic and international fiscal year-ends, approximately two-and-a-half months of Wyeths U.S. operations and approximately one-and-a-half months of Wyeths international operations are included in our consolidated financial statements for the quarter ended December31, 2009. For additional information, see Note 2. Acquisition of Wyeth. The increase in revenues and costs and expenses in the fourth quarter of 2009 primarily reflects the results of Wyeths operations as well as higher purchase accounting charges resulting from the Wyeth acquisition. (b) Restructuring charges and certain acquisition-related costs includes rest<
ructuring charges recorded in the fourth quarter of 2009 related to our acquisition of Wyeth. (c) Earnings per share in fourth-quarter 2009 was impacted by the increased number of shares outstanding in comparison with prior 2009 quarters, resulting p�"
��H
����[�
J�$ �D ���!��$�[&�1)z�+�
.J�/ 1�
/3^�5�7�:� y=� �?�CNkE�1H`�b���G����rC8
{�Y
��
���
iQ�
G�
� F���� 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�

�

�
� 

�


� � � 
� � 
� � 
�
d>�@�dd
�7 F��� � 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}
�}�$  �

�
�

�

�

�

�

�

�

�
 �
�
�
�  �
 �

�
�
 � � � 
� � 
� � 
� � 
� � 
� � 
� �
� ~ �Y@� � @ځ�A�f�8>�@�dd
�7 F���H' 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�}�}�}�}�}�$ �

�
�
�
�
�
�
�
�
 �
 �
�
�
 �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
� �
 �

�
!�
"� #~ 
 k�@
~ ��@
~ @��@
� $


� %~ 
\�@� &~ ��@� &~ ���@� &� '~ 
� �@� &~ �d�@� &~ ��@� &� (~ 
��@� &~  �@� &~ ��@� &� )~ 
z�@
~ ؤ@
~ p�@
� *~ 
Q@
~ ȃ@
~ �q@
� +~
�@
 ~ �@
 ~ ̣@
 � ,~
@r@
 ~ ��@
 ~ |��
 � -~ 
�%�@
~  ��@
~  �@
� .~ 
*�@
~ ��@
~ ��@
� /~
��@
 ~  q�@
 ~  ��@
 � 0~ 
,@
~ �S@
~ @Q�
� 1~ 
��@
~  ��@
~  ��@
� 2~ 
"@
~ 7@
~ E@
� 3~ 
!���@
~ !��@
~ !п@
� 4


� 5~ 

�^@
~ 
�]@
~ 
�]@
� 0~ 

~ 
�?
~ 
�
� 6~ 
"
�^@
~ "
^@
~ "
�]@
� 7


� 5~ 

�^@
~ 
�]@
~ 
�]@
� 0~ 

~ 
�?
~ 
�
� 6~ 
"
�^@
~ "
^@
~ "
@]@
� 8~ 
_�@
~ G�@
~ �@
� 9~ 
��@
~ ^�@
~ �@
� :�>� 08V,bbbVVVVVVVVVVV,VVV,VVVVV>�@�dd
�
�7 F���+�/S2 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}
�}�$ +�

�
�
�
�
�
�
�
�
 �
 �
�
�
 �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
� ;�
<�

=�
>� ?� @�
�@��@� A�
�m�@@�@� B�
���@�@� C�
��@��@� D�
�9�@�@� E�
2�@��@� F�
@�b@� G�
��@ ��@� H�
��@k�@� I�
?�@���@� J�
��@��@� K�
��@@N�@� L�
z�@�@� M�
�� A �"�@� N� O�
]�@4�@� P�
�@\�@� Q�
��@ޠ@� R�
���@��@� S�
��@�@� T�
���@`�@� U�
-�@ @`�@� V�
 �@�@� W�
��@��@� X�
V�@�@� Y�
�k�@�@� Z�
��@��@� [�
�@��@� \�
p��@ �@�D�l*$$$$$$$$$$$$$$$$$$$$$$$$$$$ �
!�
"�
#�
$�
%�
&�
'�
(�
)�
*�
� ]�
�N@@R@� !^�!
�{@�{@� "_�"
6�@�(�@� #`�#
�t��z�� $a�$
 ������ %b�%
@��@���@� &c�&
@�@ٱ�� 'd�'
���@ ��@� (e�(
{@g@� )f�)
��@ �1�@� *g�*
!�� A!�"�@�h�$$$$$$$$$$>�@�dd
�7 F��� z6 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}
�}�$  �

�
�
�
�
�
�
�
�
 �
 �
�
�
� h�
i�

=�
>� ?� j�
f@�g@� N� k�
;@H�@� l�
� m�
̿yA̿yA� n�
��@0�@� o�

@
@� p
�ZB �ZB� q
��B.5�B� r
����A�A���*$$$$$$22>�@�dd
�7 F���B;AwJ�K 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}
�}�$ B�

�
 �
�
�
 �
 �
 �
 �
 �
 �
 �
�
 �
�
 �
�
 �
�
 �
�
 �
�
 �
�
 �
 �
 �
�
 �
 �
�
� s�
i�

t�
u�
v�
w�
x�
y�
z�
{�
|�
}� ~�B
�a@�{@��@��������@�@P}��k�@�R@�p�@ � ~ 
R�@:mB~ 8�|�p�A��� �� �~ п@�п@E@��@ � ����@��@@��@ � ��
#######� P�@ H@ h�@ � �~ &@~ &@~  &@� �� �~ ܿ�~ ܿ�~ ܿ�� �~  �~  �~   �� �~ <�uA��SA� �� �?�@@^@�~ ��@~ ��@� ��8���� �~ ���~ ���~  ���� �~ ��.A� ���H�@]@~ Q@~  Q@� �~ 
���~ ��.A� �~ 
H�~ 9�~ @~ Q�~  Q�� �~ ��^A~ � �� b@~ �[��A@ �:@ � �~ 
��@D|B~ `�v�� ��� ��B
@W@�{@��@0�������?�@��@@��@�\@���@ � �� �~ ��@���@7@��@ � ��Ժ�Ժ��A@��� � ��
#######� P�@ M@ 8�@ � �� �~ ����~ ����~  ����� �~ �~ �~  �� �~ ��.A�DT l�TN80B8882L 8@*T*NNT80B88 �
!�
" �
#�
$ �
%�
& �
'�
( �
)�
* �
+�
, �
- �
. �
/�
0 �
1�
2 �
3 �
4 �
5�
6 �
7�
8 �
9�
: �
;�
< �
= �
>�
? �
� �� �i@@@~ �m@~ �m@� !�~ !��x�� "�~ "@�~ "@�~ " @�� #�~ #��.�� $��$@\�@W@~ $4�~ $ 4�� %�~ %
 �~ %� &�~ &
4�~ &�~ &@~ &9�~ & 9�� '�~ '��hA~ '��>�� (��(�?�q@~ (G��(�m@(@@o@ � )�~ )
0�@).5�B~ )`�v�)��� *��B*
@R@�{@�(�@�z�������@ٱ���@g@�1�@ � +�� ,�~ ,���@�,���@"@��@ � -��-
�@
�@@�@ � .��.
#######�. ��@ ,@ ��@ � /�/��A� 0��0�r�@G���0���@�t@@�@ � 1�� 2�~ 24��~ 24��~ 2 4��� 3�~ 3�~ 3�~ 3 �� 4��4�� � 5�~ 5� 6��6@`@"@~ 6`a@~ 6 `a@� 7�~ 7`�VA� 8�~ 8~ 8~ 8 � 9�~ 9�ZA� :��:�N��[@~ :I@~ : I@� ;�~ ;
Pr�~ ;� <�~ <
(�~ <�~ <@~ <$�~ < $�� =�~ =�P��=�P��Y�e� � >��>��>���.�� ?��?�j@<�7@�?�i@&@@k@ �D�l@8@*T*NNT80B @88*@8@*T8$@�
A �
� @�~ @
��@@��B~ @�r�@������ A��BA
�N@�{@6�@�t� ��@��@@�@���@{@��@ ��N>�@�dd
�7 F���1T"X 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}
�}�$ 1�

�
�
�
�
�
�
�
�
 �
 �
�
�
 �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
� ��
<�

�
!�
"� �� 1�
��@��@��@� �� ��
��@�@P�@� ��
�u@x@P{@� *�
Q@ȃ@�q@� ��
X�@� ��
���,�`t�� ��
�e@� ��
���̔�ȥ�� ��
�@@(�@� �� ��
�}�`h@t�� D�
|�@`r@��@� ��
��Ѐ�8��� ��
|�@��@��@� ��
w�@8�@H��� ��
А@}@N�� ��
�2�@ ���@ ��@� �� ��
Ԓ����`��� ��
`@�� o������� ��
���@�:�@@��@� ��
��@�@C�@� ��
���F������ ��
h�@��@�e@� ��
`�����}�� ��
��@t��@p�� ��
��� ��� ؈@� ��D&l8************************* �
!�
"�
#�
$�
%�
&�
'�
(�
)�
*�
+�
,�
-
�
.�
/�
0�
� ��
@H�@���@��@� !��!
 ��2������ "��"
�u�@�@�@� #��#
8��t��P�� $��$
@����� %��%
�������'��� &��&
�V��R@�|@� '��'
�H�@ ��� ���� (��(
N@�_��D@� )��)
b� �� ��@� *��*
��@��@��@� +��+
�@��@��@� ,�� -�~ -
���@� .�� /��/
��@��@�@� 0��0
8�@p�@�@�&�@
*************>�@�dd
�7 F���/Z 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F���"\ 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F���^ 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F���` 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����a 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����c 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����e 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����g 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����i 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����k 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� D

�


� �� �� 
���<>�@�dd
�7 F����m 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����o 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����q 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F����s 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� �

�


� �� �� 
���<>�@�dd
�7 F���yu 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� 


�


� 

� 
� 

��<>�@�dd
�7 F���lw 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� 


�


� 
� 
� 

��<>�@�dd
�7 F���_y 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� 


�


� 
� 
� 

��<>�@�dd
�7 F���R{ 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� 


�


� 
� 
� 

��<>�@�dd
�7 F���E} 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� 


�


� 
� 
� 

��<>�@�dd
�7 F���8 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� 


�


� 
� 
� 

��<>�@�dd
�7 F���+� 
d
����MbP?_
*+�
�%������" d


FXX�?�?
U}�<}

�}�$ �


�
�

�
� 


�


� 
� 
� 

��<>�@�dd
�7
����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
�����Oh��+'��0P
(�08� sshxbrl����՜.��+,��D��՜.��+,��l(
� � 4
$�,�